The sponsorship serves as a symbolic nod to the nearly five-decade gap in medical innovation for motion-induced vomiting. As the first new prescription medication approved for this condition in 47 years, NEREUS—tradipitant—aims to provide a modern pharmacological option for travelers. The branded vehicle will appear at select events throughout the 2026 season.
In section Releases
Vanda Pharmaceuticals Links NEREUS to No. 47 IndyCar Entry
Forty-seven years after the last breakthrough in motion sickness treatment, Vanda Pharmaceuticals is marking the launch of its new drug, NEREUS, by sponsoring the No. 47 car in the NTT IndyCar Series. The partnership with Rahal Letterman Lanigan Racing pairs the selective NK-1 receptor antagonist with high-speed professional motorsport.
Mihael H. Polymeropoulos, President and CEO of Vanda, noted that the collaboration reflects a shared commitment to maintaining performance under extreme conditions. While the pharmaceutical company focuses on addressing unmet medical needs, the high-speed environment of IndyCar provides a platform to highlight the drug's role in stability and focus. The move underscores Vanda’s strategy to bridge clinical advancement with high-profile public visibility.
Comments (0)
No comments yet. Be the first!